Table 2. Adverse Events in The Study Patients.
| Group A, No. (%) | Group B, No. (%) | |
| Death | 3 (1.5) | 5 (6) |
| Non-response | 21 (10) | 5 (6) |
| Dose Reduction | 39 (19) | 15 (18) |
| Neutropenia | 33 (16) | 11 (13) |
| Thrombocytopenia | 6 (3) | 4 (5) |
| Headache | 46 (23) | 20 (25) |
| Lethargy | 41 (21) | 11 (12) |
| Dizziness | 23 (12) | 8 (10) |
| Insomnia | 34 (17) | 12 (15) |
| Irritability | 67 (34) | 23(28) |
| Depression | 15 (7) | 10 (12) |
| Fatigue | 60 (30) | 19 (23) |
| Weight loss | 12 (6) | 3 (3.7) |
| Flue like syndrome | 11 (5) | 5 (6) |
| Myalgia | 65 (33) | 26 (32) |
| Arthralgia | 59 (30) | 23 (28) |
| Nausea | 11 (5) | 4 (5) |
| Diarrhea | 13 (6) | 4 (5) |
| Cough | 19 (9) | 9 (11) |
| Alopecia | 85 (43) | 33 (41) |
| Dry skin | 26 (13) | 21 (26) |
| Pruritus | 19 (9) | 3 (4) |
| Rash | 5 (2) | 3 (4) |
| Chills | 23 (12) | 13 (16) |
| Fever | 48 (24) | 23 (28) |